 |
|
Study reveals new player in sepsis-associated acute respiratory distress syndrome
January 24, 2006Every year, more than 200, 000 Americans die from sepsis, a severe illness caused by bacterial infection of the bloodstream. A study by Vikas Sukhatme and colleagues (Beth Israel Deaconess Medical Center and Harvard Medical School) now reveals that a protein called angiopoietin-2 may play a pivotal role in acute respiratory distress syndrome (ARDS), a condition that affects about 40% of patients with sepsis and worsens their prognosis.
In ARDS, small blood vessels in the lungs become leaky and release fluid. This impairs lung function, and patients experience trouble breathing and need to be put on respirators. If the condition lasts too long, the lung tissue gets damaged irreversibly. But what causes the leakage of fluid out of the blood vessels?
Blood vessels are normally lined with tightly linked cells, called endothelial cells, that form an impermeable barrier. Animal experiments had suggested that the development of this barrier is controlled by two small proteins called angiopoietin-1 (Ang-1) and angoipoietin-2 (Ang-2) together with these proteins' receptor, called Tie 2. These experiments also suggested that Ang-2 might disrupt the barrier lining the blood vessel wall. These and other observations prompted Sukhatme's team to ask whether the Tie-2 signaling pathway is affected in sepsis and, specifically, whether excess Ang-2 levels might promote the leakage of fluid from the blood vessels that underlies ARDS.
They tested whether excess levels of Ang-2 occur in sepsis and could cause leakiness of lung blood vessels in three different ways: First, they measured the level of Ang-2 in the blood of patients with sepsis. Second, they tested whether blood from patients with sepsis could cause leakiness in blood vessels grown in the laboratory. Finally, they tested whether elevated levels of Ang-2 affect the permeability of lung blood vessels in mice. They found that Ang-2 levels are elevated in patients with sepsis, especially in those who have acute lung injury. Over the course of the disease, Ang-2 levels mirror a patient's condition: they go up as the condition worsens and go down as the patient gets better. They then showed that treating blood vessels grown in the laboratory with blood from patients with ARDS made these blood vessels leaky. They could get the same results with treating the blood vessels with just Ang-2, and they could reverse the leakiness by subsequent treatment with Ang-1, a molecule that antagonizes the actions of Ang-2. Finally, consistent with a key role for Ang-2 in sepsis-associated ARDS, they found that injecting Ang-2 into the blood of healthy mice caused ARDS-like symptoms in these animals.
These results suggest that Ang-2 can serve as a marker of acute lung injury and might be a key player in sepsis-associated ARDS. They raise the possibility that reducing Ang-2 levels in patients might help to prevent or improve this dangerous complication in patients with sepsis. Future studies in patients with sepsis, and in patients with ARDS that is not caused by sepsis, are needed to clarify the roles of Ang-2 and Tie-2 in ARDS and the suitability of Ang-2 as a target for therapy.
Public Library of Science
They tested whether excess levels of Ang-2 occur in sepsis and could cause leakiness of lung blood vessels in three different ways: First, they measured the level of Ang-2 in the blood of patients with sepsis. Second, they tested whether blood from patients with sepsis could cause leakiness in blood vessels grown in the laboratory. Finally, they tested whether elevated levels of Ang-2 affect the permeability of lung blood vessels in mice. They found that Ang-2 levels are elevated in patients with sepsis, especially in those who have acute lung injury. Over the course of the disease, Ang-2 levels mirror a patient's condition: they go up as the condition worsens and go down as the patient gets better. They then showed that treating blood vessels grown in the laboratory with blood from patients with ARDS made these blood vessels leaky. They could get the same results with treating the blood vessels with just Ang-2, and they could reverse the leakiness by subsequent treatment with Ang-1, a molecule that antagonizes the actions of Ang-2. Finally, consistent with a key role for Ang-2 in sepsis-associated ARDS, they found that injecting Ang-2 into the blood of healthy mice caused ARDS-like symptoms in these animals.
These results suggest that Ang-2 can serve as a marker of acute lung injury and might be a key player in sepsis-associated ARDS. They raise the possibility that reducing Ang-2 levels in patients might help to prevent or improve this dangerous complication in patients with sepsis. Future studies in patients with sepsis, and in patients with ARDS that is not caused by sepsis, are needed to clarify the roles of Ang-2 and Tie-2 in ARDS and the suitability of Ang-2 as a target for therapy.
Public Library of Science
Sepsis Current Events and Sepsis News RSSA Second Skin
Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections.
Progress made on group B streptococcus vaccine
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible.
Canadian scientists link fat hormone to death from potentially deadly blood infection
A new Canadian study has found that lower-than-normal levels of a naturally-occurring fat hormone may increase the risk of death from sepsis-an overwhelming infection of the blood which claims thousands of lives each year.
OMRF scientists discover promising new path for treating traumas
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.
Scientists create NICE solution to pneumonia vaccine testing problems
Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB).
Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.
Review: Pneumococcal conjugate vaccines effective at preventing child deaths
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.
Key feature of immune system survived in humans, other primates for 60 million years
A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.
Discovery may lead to powerful new therapy for asthma
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.
Abnormal Brain Circuits May Prevent Movement Disorder
Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's.
More Sepsis Current Events and Sepsis News Articles
 |
Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care by Jean-Marc Cavaillon (Editor), Christophe Adrie (Editor) Providing definitions, clinical features and epidemiology, Sepsis and Non-infectious Systemic Inflammation adopts a comprehensive approach, describing in detail the various physiological systems involved. As such, this unique handbook and reference work is the first to combine sepsis and non-infectious SIRS, reviewing both the biological and medical aspects of these two important syndromes. The whole is rounded off with a discussion of past, present and future therapies. |
 |
Sepsis: New Strategies for Management by Jordi Rello (Editor), Marcos I. Restrepo (Editor) Sepsis is an important public health problem around the world. Severe sepsis carries significant morbidity, mortality and high costs. The incidence of sepsis is increasing because of the aging population, the growing number of immunocompromised hosts, the increasing use of invasive procedures, and, to a lesser extent, antibiotic resistance among pathogens. Despite recent advances in the pathogenesis, diagnosis, and therapeutic approaches the mortality rate associated with this condition remains high. Therefore, the goal of "Sepsis: New Strategies" is to review novel targets to be considered in patients with severe sepsis and to assess new developments for patients with sepsis originating in the respiratory tract. |
 |
Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine) by Edward Abraham (Editor), Mervyn Singer (Editor) There have been tremendous advances in understanding the cellular mechanisms involved in sepsis and contributing to the development of multiple organ dysfunction and mortality in this setting. The chapters in this book provide up-to-date insights into important pathways that are initiated by sepsis. |
 |
Primordial Notions Delta 2001-2004 Monstrum Sepsis (Primary Contributor) |
 |
Deep Sea Creatures by Monstrum Sepsis Monstrum Sepsis (Performer) Monstrum Sepsis emerges from the depths to bring you a new full length album of exquisitely inspired and arranged electronic music. Written and composed by Rob Wentz with additional instrumentation from Paul Karlik and guest vocals from Shikhee of Android Lust. Originally limited to 300 copies this new pressing features a few artwork enhancements as well as two new tracks. These 12 tracks will lift you off your feet in a sonic array of pulsing synthetics, disruptive modulations, sweeping strings and incredibly infectious rhythms. |
|
Bacteria Sepsis: Video 1 of 3 [VHS] Starring: Diane Charsha | |
 |
Management of Sepsis: the PIRO Approach by Jordi Rello (Editor), Emili Díaz (Editor), Alejandro Rodríguez (Editor) Sepsis is a very important public health problem. It is widely acknowledged that the severe inflammatory response syndrome/severe sepsis paradigm fails to stratify sepsis patients adequately. This book reviews in detail how sepsis should be managed on the basis of a novel approach to staging. The PIRO (predisposing factors, infection, response, organ dysfunction) model was first proposed at the start of the decade on a theoretical basis and has now been translated into a practical approach for use at the bedside. It is loosely based on the TNM staging system for cancers, with points being allocated to each of the four aforementioned key characteristics of the septic process. The proposed PIRO framework facilitates evaluation of factors that are important in the pathogenesis of severe... |
 |
Sepsis (Competency-Based Critical Care) by Simon V. Baudouin (Editor) Sepsis is a serious medical condition, resulting from the immune response to a severe infection. Septicaemia is sepsis of the bloodstream caused by bactemeria, which is the presence of bacteria in the bloodstream. The term septecaemia is also used to refer to sepsis in general. In the US, sepsis is the leading cause of death in non-coronary ICU patients, and the tenth most common form of death overall. Sepsis is common and also more dangerous in the elderly, immunocompromised, and critically ill patients. It occurs in 1-2% of all hospitilizations and accounts for as much as 25% of all ICU bed utilization. It is a major cause of death in intensive care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to more than 60% for septic shock. The... |
 |
Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs) by Novartis IMPACT 1.5 is a calorically dense, patented enteral formula containing arginine, dietary nucleotides and fish oil. Each member of the Impact family of products has a unique and patented formula that has been demonstrated in clinical trials to improve patient outcomes. Specifically, patients who received an Impact formula in clinical trials developed fewer infections and had shorter hospital stays than those patients fed enteral formulas. Impact 1.5 formula is intended for patients with fluid restrictions or high energy needs. Impact 1.5 is a Medical Food- consumers should consult with their physician on the use of this product. 250 ml Cans, 24/Case (202.8 oz/Case) Provides nutritional support for immuno compromised patients who require fluid restriction or have higher energy needs such... |
 |
Primordial Notions Gamma 1996-2000 Monstrum Sepsis (Primary Contributor) |
| © 2009 BrightSurf.com |